# The National Drug Abuse Clinical Trials Network: New England Consortium Node

> **NIH NIH UG1** · YALE UNIVERSITY · 2020 · $566,879

## Abstract

Project Abstract
This is a competing renewal application for the New England Consortium Node (NECN). The NECN, led by
Kathleen Carroll, PhD, of Yale, and Roger Weiss, MD, of Harvard, has a track record of outstanding
productivity in the Clinical Trials Network (CTN), with leadership of 4 highly successful completed trials, high
levels of study participation, excellent recruitment and retention, and 38 peer-reviewed CTN publications during
the current funding period. NECN investigators have published the 3 most widely cited papers in the history of
the CTN and are currently leading 6 CTN trials. With the recent CTN emphasis on SUD research in general
health settings, we have added a third PI, Gail D’Onofrio, MD, currently leading 2 large CTN trials in
emergency departments (EDs).
The primary aims of this competing renewal application are to: 1) Continue to extend the NECN’s strong
clinical research infrastructure into an even wider range of healthcare settings, and 2) Propose a series of
studies in an array of healthcare settings to improve interventions for a wide variety of people who use
substances, ranging from those with risky substance use to severe substance use disorders (SUDs). These
studies, building on previous work of NECN investigators, address critical issues that face practitioners
throughout the healthcare system. Proposed studies include the following:
1. Screening, Brief Intervention and Referral to Treatment (SBIRT) vs. SBI with Onsite Computer-based CBT
 for Stimulant Use Disorder in Primary Care
2. A Randomized Controlled Trial to Prevent or Reduce Substance Use by Youths with Chronic Illness
3. Testing an evidence-based psychosocial treatment for stimulant use disorder and concurrent HIV sexual
 risk among men who have sex with men
4. Implementation of the Addiction “Bridge Clinic” Model for General Medical Settings
The NECN can provide clinical research access to virtually any substance use population and setting, including
primary and specialty care for children and adults, medical and emergency care, medical/surgical
hospitalization, psychiatric treatment, and SUD specialty care. Our Node has developed state-of-the-art health
information technologies that can be leveraged for CTN studies. The NECN has the ideal mixture of cutting-
edge investigators, including national leaders in addiction medicine and specialty care; superb, research-
friendly clinical sites; and a track record of innovation, leadership, collaboration, and outstanding productivity in
the CTN. We have demonstrated our ability to conduct cost-efficient pragmatic trials of treatments that have
directly improved clinical practice. We have the scientific expertise and the clinical and research infrastructure
to play key roles in a variety of SUD studies in both general healthcare facilities and specialty SUD treatment
programs. We are well prepared to continue to play a key role in all aspects of the CTN.

## Key facts

- **NIH application ID:** 10164519
- **Project number:** 3UG1DA015831-19S2
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** Gail D'Onofrio
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $566,879
- **Award type:** 3
- **Project period:** 2002-09-30 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10164519

## Citation

> US National Institutes of Health, RePORTER application 10164519, The National Drug Abuse Clinical Trials Network: New England Consortium Node (3UG1DA015831-19S2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10164519. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*